Medical Health Cluster

Antibody Cocktail

Antibody Cocktail Reduces Chance of Developing COVID

A one-time dose of two long-acting monoclonal antibodies reduced the risk of developing symptomatic COVID by 77% in comparison with placebo (P < .001) in a randomized, double-blind, placebo-controlled, phase 3 trial in adults, according to researchers who on Thursday presented results at the Infectious Disease Week (IDWeek) 2021 Annual Meeting. […]

Read More